Association of Appearance of Conflicts of Interest With Voting Behavior at FDA Advisory Committee Meetings-A Cross-sectional Study
To ensure objectivity on the 49 advisory committees (ACs) of the US Food and Drug Administration (FDA), the FDA reviews disclosure statements submitted by members for 2 potentially disqualifying types of financial conflict of interest (COI): "section 208 conflicts" (regulated under 18 USC §208 1 ) and, for those without section 208 conflicts, "section 502 conflicts" (regulated under 5 CFR §2635.502 2 ). While section 208 conflicts are created by current financial interests, section 502 conflicts are typically created by past financial interests or personal and business relationships that could create the appearance of a conflict. For both, the FDA may either exclude the individual from participation or allow participation when permitted by statute. The FDA publicly discloses section 208 conflicts 3 but not section 502 conflicts and has recently requested comments about whether these conflicts should be publicly disclosed. 4, 5 We examined the prevalence of section 502 conflicts and their associations with voting behavior at FDA AC meetings.
Methods | We obtained internal agency information for AC meetings with votes on drugs and devices held between 2008 and 2014 for which COI screening was required. For meetings with section 502 conflicts present, we determined the prevalence and characteristics of both section 208 and section 502 conflicts and, for meetings related to particular products, assessed whether members with section 502 conflicts were more likely to vote with the majority than were members without these conflicts. For meetings with no section 208 conflicts and where the vote was not unanimous, we assessed whether the prevalence of section 502 conflicts was associated with the percentage of votes favorable to the product and with the meeting outcome. Finally, we examined whether excluding members with section 502 conflicts would have changed the meeting outcome. Institutional review board approval was not required because the study was not considered human subjects research.
Results | Of 385 AC meetings that met entry criteria, 27.3% (n = 105) included at least 1 voting member with a section 502 conflict; there was no trend over time. Of 1482 voting members in these meetings, 12.6% (n = 187) had section 502 conflicts only; 0.8% (n = 12) had section 208 conflicts only, and 0.9% (n = 14) had both. More detail is reported in Table 1 . Individuals with only section 502 conflicts were typically organizational officers (36.9%; n = 69), had conflicts with sponsoring firms (89.3%; n = 167), and had imputed COIs (ie, COIs assigned based on members' personal relationships or employment) (61.0%; n = 114). Voting members with only section 208 conflicts were more likely than those with 502 conflicts to have conflicts with competing firms (58.3% [n = 7] vs 8.6% [n = 16]; Pearson χ 2 P < .001) but were otherwise similar. The median values of section 502 and 208 conflicts were $30 000 and under $50 000, respectively (the financial value of section 208 conflicts is reported in ranges). Of 151 votes on specific medical products by members with only section 502 conflicts, 132 (87.4%) concurred with the majority (Table 2) . We found no association between the prevalence of section 502 conflicts and voting outcomes. Excluding members with section 502 conflicts generally would have produced voting margins more favorable to the product, but in no instance would the meeting outcome have changed between favoring and opposing the product. In 1 instance, excluding 2 members with only a section 502 conflict would have led to a tie vote rather than a vote opposing the product.
Discussion | Between 2008 and 2014, about a quarter of FDA AC meetings that met entry criteria included at least 1 participant with a section 502 conflict. Members with section 502 conflicts had voting patterns similar to those without such conflicts; there was no association between section 502 conflicts and meeting outcomes.
The study limitations were as follows: (1) including only meetings where at least 1 member had a section 502 conflict; (2) small sample sizes, particularly in the voting analyses; and (3) inability to control for other factors that might (Table 1 and Table 2 ).
Discussion | In this nationally representative study, we found that previously reported declines in PSA testing have not continued in recent years, and approximately a third of men 50 years or older still receive routine PSA testing. Physicians interested in deadopting PSA testing may have done so, closely following the USPSTF recommendation and the media attention that came with it. In addition, other public health organizations still support PSA testing, 2 albeit with shared decision making, and physicians may have chosen to continue to offer PSA testing based on their beliefs about screening and interpretation of clinical trial results. We relied on self-reported PSA testing, which is subject to recall bias, and some men may not have been informed of testing, which is a limitation of the study. 5 However, this study provides data on contemporary nationwide PSA testing patterns.
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